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after WBI; 1.4% after APBI; p=0.04) difference: -2% (95% CI: 
-3.9 – -0.1%). The rate of excellent/good cosmetic results 
judged by the patients was 87.2% versus 90.4% (p=0.06) in the 
WBI and APBI group, and 86.7% versus 88.2% (p=0.07) scored 
by the physicians. 
 
Conclusion: The 5-year toxicity profile and cosmetic results 
are similar at patients treated with BCS followed by either 
APBI using iBT or conventional WBI with tumour bed boost. A 
non-significant trend towards less late skin side effects and 
better cosmetic results has been observed in the APBI arm. 
 
Award Lecture: K. Breur Award Lecture  
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Traditional delivery of radiotherapy uses daily fractions of 
1.8-2Gy building up to a therapeutic dose over 6 to 8 weeks 
of treatment. This reflects application of the fundamental 
principles of radiobiology in which repair, repopulation, 
reoxygenation and redistribution in the cell cycle are 
considered important in defining the response of tumour and 
normal tissue. However the relevance of this approach in an 
era of more precise image guided dose delivery where the 
exposure of normal tissue is minimised and high individual 
doses can be delivered must be questioned. There are two 
scenarios in which single dose radiotherapy has been 
evaluated and found to be highly effective. The first is in the 
extensive work which has been undertaken over several 
decades to establish the role of single dose palliative 
radiotherapy. The best example of this is in the management 
of metastatic bone pain where single dose radiotherapy is 
considered the standard of care but other palliative scenarios 
in non-small cell lung cancer, oesophageal cancer, rectal, 
bladder and prostate cancer are also relevant to this 
approach. The second scenario is that of curative treatment 
for localised prostate cancer using high dose rate 
brachytherapy (HDRBT). Dose escalation using HDRBT is well 
established as an effective therapy in prostate cancer and 
there is now a substantial database of large published series 
using HDRBT alone demonstrating high biochemical control 
rates. It is now feasible to deliver single dose radical 
radiotherapy using HDR BT with low toxicity and high disease 
control rates challenging the conventional and modest 
hypofractionation schedules used with external beam. The 
relevance of conventional fractionation can now be 
challenged in the era of modern image guided radiation 
delivery for both palliative and radical treatment. A 
sufficiently high dose delivered accurately to the target 
volume is all that is required. 
 
 
Joint Symposium: ESTRO-ASTRO: In room adaptive imaging 
with a focus on MRI  
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The MRI linac originates from the desire to bring sight to the 
radiation oncologist. So to offer truly simultaneous soft-tissue 
visualization during radiation delivery. In UMC Utrecht, in 
collaboration with Elekta and Philips, a hybrid 1.5 T MRI 
radiotherapy system has been developed to facilitate this. 
Later also other systems emerged; in the Cross Cancer 
Institute in Edmonton a rotating 0.5 T MRI linac has been 
developed and the Viewray company has launched a 0.3 T 
Cobalt 60 system into the clinic. The systems will be briefly 
presented.  
The common ground of the systems is the soft-tissue 
guidance. As will be shown, MRI offers a wealth of contrasts 
for anatomical and physiological information but also motion 
data. Exploiting these data for treatment guidance and 
treatment adaptation requires a new workflow with more on-
line decisions, such as contouring, plan adaptation or full re-
planning to initialize the treatment. Moreover, the 
continuous anatomical imaging during radiation delivery 
enables new direct anatomical triggers for gating and 
tracking, but equally important, this imaging can be used for 
dose reconstruction while accounting for intra-fraction 
motion. The latter is a valuable input for dose response 
assessment and can also be used for quality assurance (QA) 
purposes. 
The QA for these systems need to be revisited, not only 
because of the new on-line plan adaptations but also due to 
the fact that the dose is delivered in the presence of a 
(perpendicular or parallel) magnetic field. This will alter the 
dose distribution which needs to be verified. Also the 
radiation detectors are potentially affected and their 
performance need to be validated (and corrected if 
necessary) for use in the presence of a magnetic field. This 
implies new machine QA , patient QA and workflow QA 
procedures. 
The promise of hybrid MRI linac technology is to enable real-
time plan adaptations in order to maximize the dose to the 
target while continuously minimizing the dose to the 
surrounding organs at risk. The efforts to move from pre-
treatment planning to once daily (on-line) plan adaptation 
and ultimately to real-time plan adaptations will be 
presented. 
In conclusion, the technology of hybrid MRI radiotherapy 
systems is there while the full clinical value needs to be 
established. This is an exciting new clinical arena and at the 
same time poses new challenges for on-line and ultimately 
real-time, adaptive radiotherapy. 
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Purpose: We report on the first two years of clinical 
operation of the first magnetic-resonance imaging-guided 
radiation therapy (MR-IGRT) program, experiences with 
patient treatments, and implications for future 
developmental and clinical work. We previously reported on 
initial clinical implementation of this system. = The purpose 
of this work is to analyze clinical practicality of MR-IGRT and 
implementation of online adaptive RT.  
 
Methods and Materials: The MR-IGRT system consists of a 
split 0.35T MR scanner straddling three 60Co heads mounted 
on a ring gantry, each head equipped with independent 
doubly-focused multileaf collimators. The MR and RT systems 
share a common isocenter, enabling simultaneous and 
continuous MR imaging during RT delivery. The system is also 
capable of online plan adaptation where patients can be 
imaged, planned, verified, and treated all in a single 
treatment session. To assess the clinical practicality of the 
system, makeup of treated cancer sites, distribution of 
available treatment techniques, total number of patients, 
maximum number of patients treated daily, and the 
utilization of advanced treatment techniques were 
evaluated. The system was clinically implemented in January 
of 2014 and data was collected over a 24 month consecutive 
period. The adaptive feature was clinically implemented in 
September of 2014.  
 
Results: During the initial 2 years of the operation, more 
than 20 cancer sites in 263 patients were treated. The 
maximum number of daily treatments was 18. Top 3 treated 
cancer sites were breast, lung, and bladder with 22%, 13%, 
and 9% of the total treatments, respectively. The utilization 
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of IMRT, SBRT, and 3D treatments was 50%, 28%, and 
22%,respectively. More than 150 real time adaptive fractions 
were delivered to more than 45 patients. We have also 
demonstrated that the system is capable of determining true 
delivered doses based on daily MR images.  
 
Conclusions: Based on the first two years of clinical 
operation, routine MR-IGRT program is practical, with ability 
of treating a broad spectrum of cancer sites, significant 
number of patients in a day, and systematic delivery of 
advanced and adaptive treatments. 
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The MR-linac combines a 1.5 Tesla MRI and a modern 7MV 
Linac into a single device that can simultaneously produce 
diagnostic quality MRI images and deliver highly conformal 
IMRT based treatments. The introduction of in room MR-linac 
based imaging allows for superior soft tissue contrast of 
tumor and surrounding normal tissues. This functionality 
enables enhanced re-positioning and adaptive radiation 
therapy to account for inter-treatment positioning errors, 
organ deformation, organ movement, and tumor response. 
Additionally, this combined device provides functionality to 
account for intra-treatment motion and has the potential to 
acquire multi-parametric functional sequences at the time of 
treatment. 
The addition of the MR-linac to a radiation therapy clinic 
poses novel challenges related to the the presence of the 
magnetic field and the configuration of the device. Prevailing 
regulations concerning room access, shielding, and adjacency 
to other treatment units and medical equipment must be 
considered when siting the device. Personnel must possess or 
acquire the skill sets and competencies to safely operate an 
MRI and Linac treatment machine. This training should be in 
place prior to installation of the device. Experience with MRI 
based simulation and treatment planning is also a 
prerequisite for MR-linac based treatment delivery. MRI 
based simulation requires attention to the size and material 
of patient positioning devices, MRI coil and table top design. 
Optimal MRI sequences to facilitate region specific tumor and 
normal tissue delineation that may differ from institutional 
diagnostic sequences must be developed. Image distortion is 
routinely managed as part of modern MRI imaging but the use 
of MRI for simulation and the MR-linac for guidance and 
treatment requires a QA process that is nuanced to these 
specific workflows.  
It is anticipated that the work flow for the MRI-linac device 
will be divided into two general scenarios. The first utilizes 
pre-treatment MRI images for patient repositioning to correct 
translational and or rotational errors. This is similar to the 
current cone beam CT image guidance workflow with the 
addition of superior soft tissue contrast. Additionally, the 
intra-fraction imaging will provide superior ability to manage 
tumor motion. The second approach adds plan adaption to 
the MRI based treatment guidance workflow to account for 
deformation, volume, and independent motion changes of 
the targets and organs at risk. The frequency of online or 
offline adaption will depend on the characteristics of tumor 
response and anatomical location.  
An international research consortium has been formed to 
allow for an evidence-based introduction of the MR-linac 
technology and to address how the technology could be used 
to achieve an optimized radiation treatment approach in 
terms of tumor control and toxicity. The MR-linac consortium 
structure is outlined in Figure 1. Nine tumor site groups have 
been selected to start consortium based clinical studies 
based on the expected clinical benefit (either increased local 
control, survival, decreased toxicity or improved quality of 
life). The first nine consortium-broad tumor sites include: 
rectum, esophagus, oropharynx, pancreas, prostate, breast, 
cervix, brain and lung. Each consortium institute coordinates 
one or more Tumor Site Groups (TSG). To achieve the clinical 
introduction of the MR-linac in a safe and step wise manner, 
an adapted version of the IDEAL framework, the R-IDEAL 
(Radiotherapy, Idea, Development, Exploration, Long-term 
study) framework, will be used to conduct the proposed 
prerequisite imaging studies and clinical treatment studies.  
 
 
 
Figure 1. Organizational structure clinical working groups MR-
linac Consortium (CSC-clinical steering committee, MAB-
methodology advisory board, DMTF-data management task 
force, TSG-tumor site group) 
References: McCulloch P, Altman DG, Campbell WB, et. al. 
No surgical innovation without evaluation: the IDEAL 
recommendations. Lancet 2009:374:1105-12 
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Soon after the introduction of MRI in radiology it became part 
of treatment planning in radiotherapy and in brachytherapy. 
Especially in gynecological brachytherapy MRI was used 
during the process of target definition. But also in other 
clinical sites MRI before brachytherapy became an essential 
tool for correct staging, treatment decision making and 
target volume definition. The important point was the use of 
MRI with the brachytherapy applicators in-situ. By this 
process the image series contain both, the delivery device 
and the anatomy including tumour, target and organs at risk. 
This enables a real adaptive planning strategy, as the 
treatment planning is based directly on these image series. 
Imaging of a fixed geometry of delivery device inside the 
anatomy is not different to in-room imaging used for external 
beam with a linac or other device as delivery device outside 
the patient. The aim of in room imaging is to depict the 
situation during dose delivery as close as possible. The 
question is how much change of the target and organs at risk 
happens between imaging and dose delivery. In external 
beam this is performed almost simultaneously without 
essential changes, while in brachytherapy the movement of 
patients from an imaging room to a treatment room might 
impose changes. This question was analyzed and debated for 
years, often using inappropriate methodologies as 
registration to bony landmarks. Only recently multicenter 
studies showed that for cervix cancer brachytherapy for 
example the relation of applicators to target is stable with 
minor variations. However, more variation may occur for 
adjacent OARs. Various methods are investigated on how to 
minimize such uncertainties. One is to perform MRI in-room 
